<DOC>
	<DOC>NCT01496690</DOC>
	<brief_summary>The PACS study aims to investigate the efficacy and tolerability of pregabalin for schizophrenic patients that suffer from comorbid anxiety. The study design is an 8 week flexible dosage, randomized placebo controlled. The study population is patients diagnosed with ICD-10 schizophrenia and age 18-65. Patients are recruited from outpatient clinics from entire Denmark.</brief_summary>
	<brief_title>Pregablin for Anxiety-comorbidity in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Ages 1865 years An ICD10 schizophrenia diagnosis F20.020.3 or F20.9 Stable dosage of psychotropic 4 weeks before inclusion Hamilton Anxiety Scale total score &gt; 15 Positive and Negative Syndrome Scale for Schizophrenia total score &lt; 70 The Calgary Depression Scale for Schizophrenia total score &lt; 10 Fertile women: Contraception during the trial Screatinin within normal reference range Signed informed consent and power of attorney Significant substance abuse QTc &gt; 480 milliseconds Severe dysregulated diabetes For women: Pregnancy or breastfeeding Confinement in accordance with the Danish Law of Psychiatry Concrete suicidally Known hypersensitivity or allergic reaction to the active ingredient of the drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Anxiety-comorbidity to schizophrenia</keyword>
	<keyword>Double-blinded randomized placebo controlled trial</keyword>
	<keyword>Pregabalin</keyword>
</DOC>